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Background: In gout, long-term urate-lowering therapy (ULT) promotes dissolution of tissue urate crystal deposits.
However, no studies using combined xanthine oxidase inhibition and uricosuric ULT have focused on clinical outcomes
or adverse events (AEs) beyond 12months of therapy. Our objective in the present study was to examine efficacy and
long-term safety in patients with tophaceous gout receiving febuxostat plus lesinurad as combination therapy.
Methods: Patients receiving combined lesinurad and febuxostat in the 12-month core CRYSTAL study continued at the
same doses in the extension study (“200CONT”, “400CONT”), whereas those receiving only febuxostat 80 mg were
randomized to lesinurad 200 or 400 mg with febuxostat (“200CROSS”, “400CROSS”). The primary endpoint was the
proportion of patients experiencing complete resolution (CR) of at least one target tophus by extension month
(EM) 12. The key secondary endpoint was mean rate of gout flares requiring treatment from the end of EM 2 to
the end of EM 12. Secondary endpoints included reduction in the sum of areas for all target tophi. Safety assessments
included AEs and laboratory data for the entire extension study (median length of lesinurad exposure, 800 days).
Results: Of 235 patients completing the core study, 196 (83.4%) enrolled in the extension: 200CONT (n = 64),
200CROSS (n = 33), 400CONT (n = 65), and 400CROSS (n = 34). At EM 12, 59.6%, 43.5%, 66.7%, and 50.0% of patients,
respectively, had CR of at least one target tophus. The sum of areas for all target tophi was reduced by 76.4%, 58.1%,
77.5%, and 62.8%, respectively. The adjusted mean (SE) rates of gout flares requiring treatment from the end of EM 2 to
the end of EM 12 were 0.6 (0.19), 1.3 (0.48), 0.2 (0.08), and 1.9 (0.93), respectively. Target sUA < 5.0 mg/dl was achieved
by 77.1%, 79.2%, 88.5%, and 71.4% of patients, respectively. Exposure-adjusted incidence rates of treatment-emergent
adverse events (TEAEs) and renal-related TEAEs in the core study were not increased with prolonged lesinurad
exposure in the extension study.
Conclusions: Patients receiving lesinurad plus febuxostat therapy for 2 years continued to be at sUA target. Patients
exhibited a progressive increase in CR of at least one target tophus, progressive reduction in tophus size, and reduction
of gout flares requiring treatment over the second year, with AEs consistent with those observed in the core study.
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Gout is characterized by increased body urate stores,
reflected in elevated serum urate (sUA) levels (hyper-
uricemia), and deposition of monosodium urate crystals
in joints and other tissues. Gout causes recurrent flares
of acute inflammatory arthritis. When hyperuricemia is
inadequately treated in gout, the disease can progress
over time to palpable tophus formation and chronic
erosive arthritis [1]. The goal of long-term management
of gout is to reduce and maintain sUA below saturating
levels (> 6.8 mg/dl), typically < 6.0 mg/dl, or < 5.0 mg/dl
for patients with more severe gout, including palpable
tophi [1, 2]. Sustained lowering of sUA reduces the vol-
ume of monosodium urate crystals, lowers the incidence
of gout flares, and promotes tophus resolution [3–5]. The
recommended first-line urate-lowering therapy (ULT) is a
xanthine oxidase inhibitor, either allopurinol or febuxostat
[1, 2], in order to lower production of urate [6]. For pa-
tients who cannot achieve their sUA target with a medic-
ally appropriate dose of a xanthine oxidase inhibitor,
treatment guidelines provide the option of combining the
xanthine oxidase inhibitor with a uricosuric agent [1, 2].
Uricosuric therapies target renal underexcretion of uric
acid, which contributes to hyperuricemia in most people
with gout [7].
Lesinurad is a uricosuric agent recently approved in the
United States and Europe at a 200-mg oral dose in com-
bination with a xanthine oxidase inhibitor for the treat-
ment of hyperuricemia associated with gout in patients
who fail to achieve sUA target with a xanthine oxidase in-
hibitor alone [8]. Lesinurad inhibits the urate transporter
URAT1, which is responsible for reabsorption of urate
from the renal tubule lumen [9]. By inhibiting URAT1,
le-sin-ur-ad increases excretion of uric acid and thereby
lowers sUA [10, 11]. Lesinurad thereby offers a comple-
mentary mechanism of action to xanthine oxidase inhibi-
tors. Although lesinurad alters the clearance of oxypurinol,
the active metabolite of allopurinol [12], lesinurad does not
alter the clearance of febuxostat [10].
The efficacy and safety of lesinurad (200 or 400mg, orally,
once daily) in combination with febuxostat 80mg compared
with febuxostat 80mg alone was investigated in patients
with gout and palpable tophi (“tophaceous gout”) in a
12-month, randomized, double-blind, placebo-controlled,
multicenter study (CRYSTAL [Combination Treatment
Study in Subjects with Tophaceous Gout with Lesinurad
and Febuxostat]; ClinicalTrials.gov, NCT01510769). The pri-
mary study endpoint was the proportion of patients achiev-
ing the sUA target of < 5.0mg/dl at the month 6 visit.
Lesinurad 400mg in combination with febuxostat 80mg
significantly increased the proportion of patients achieving
the sUA target at the month 6 visit versus febuxostat 80mg
alone (p < 0.0001), whereas lesinurad 200mg daily plus
febuxostat 80mg did not (p= 0.13) [13]. At all other timepoints, more patients in the lesinurad 200-mg group
achieved the sUA target. The safety profile of lesi-
nurad at the approved 200-mg dose combined with
febuxostat 80 mg was comparable to febuxostat 80 mg
alone, except for the higher incidence of predomin-
antly reversible serum creatinine (sCr) elevations. The
present study assessed the efficacy and long-term
safety of lesinurad in combination with febuxostat in
patients who completed CRYSTAL and entered an ex-
tension study (NCT01808144).
Methods
Study design and medications
The CRYSTAL extension study was performed at 73 study
sites in six countries: United States, Canada, Poland,
Switzerland, Australia, and New Zealand. The study was
conducted in accordance with the ethical principles of
good clinical practice according to the International Con-
ference on Harmonisation Harmonised Tripartite Guide-
line. Patients provided informed written consent and had
the right to withdraw at any time.
All patients who completed treatment in the 12-month
CRYSTAL study (“core study”) were eligible to enter the
optional extension study, which was planned to include a
treatment period of up to approximately 5 years. Patients
who completed the core study [13] on lesinurad 200mg
plus febuxostat 80mg or lesinurad 400mg plus febuxostat
80mg continued at the same lesinurad and febuxostat
doses in the extension study (“200CONT” and “400CONT,”
respectively), without scheduled interruption in study medi-
cations (Fig. 1). Patients who completed the core studies on
febuxostat 80mg alone (placebo) were randomized 1:1
using an interactive voice/web response system to receive
either lesinurad 200mg plus febuxostat 80mg or lesinurad
400mg plus febuxostat 80mg in the extension study
(“200CROSS” and “400CROSS,” respectively). The lesi-
nurad dose was blinded until database lock of the core
study and all patients had reached at least month 12 in the
extension study, after which patients transitioned to
open-label treatment. No efficacy measurements were
planned beyond month 12 of the extension, whereas safety
was followed throughout the extension. In a protocol
amendment to the extension study, following a review of
the efficacy and safety data at interim (12-month) analysis,
patients receiving lesinurad 400mg were decreased to the
200-mg daily dose; the efficacy analyses were completed be-
fore the dose change.
Gout flare prophylaxis was given to all patients in the
extension study to maintain blinding of the core study.
As in the core study, flare prophylaxis consisted of col-
chicine 0.5 or 0.6 mg daily (depending on local dose per
tablet) or a nonsteroidal anti-inflammatory drug with
or without a proton pump inhibitor if patients had an
intolerance/contraindication to colchicine. Prophylaxis
ab
Fig. 1 Proportion of patients with serum urate (sUA) < 5.0 mg/dl (a) and mean (SE) sUA levels (b) in the core study and extension study: observed
cases (intention-to-treat population). CONT Continuation of lesinurad treatment, CROSS Crossover from core study placebo to lesinurad treatment
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through extension month 2; continuation after extension
month 2 was at the discretion of investigators but was not
to exceed 6months. In cases of sCr more than 1.5 times
baseline, patients were advised to drink ≥ 2000ml of
fluids, and if urine pH was < 6.5, investigators were to
consider initiating a urinary alkalinizing agent. Treatment
compliance was assessed by maintaining medication-
dispensing records and by verification of returned and
remaining study medications.
Patients
For entry to the 12-month core CRYSTAL study, pa-
tients with gout aged 18–85 years on ULT currently or
in the past, as well as those who had never received a
ULT, were eligible. sUA was required to be ≥ 8.0 mg/dl
for patients not receiving ULT and ≥ 6.0 mg/dl for those
receiving ULT. Patients were also required to have at
least one measurable tophus on the hands/wrists and/
or feet/ankles ≥ 5 and ≤ 20 mm in the longest diameter
(length). Patients were given febuxostat 80 mg daily for3 weeks before randomization to lesinurad (200 or 400
mg daily) or placebo added to febuxostat. To enter the
extension study, patients must have completed treat-
ment in the core study.
Patients were discontinued from the extension study if
they withdrew consent, developed an adverse event (AE)
or laboratory abnormality requiring treatment discontinu-
ation, experienced an sCr elevation three or more times
baseline before the first lesinurad dose or ≥ 4mg/dl or an
estimated creatinine clearance < 30ml/min on repeated
measurements, or developed a kidney stone.
Assessments
Baseline assessments for the extension study were per-
formed at the month 12 visit of the core study. Assess-
ments for efficacy and safety during the extension study
were performed monthly at months 1–12 (blinded phase),
and safety assessments were additionally performed every
subsequent 2months until patient withdrawal or study
termination (open-label phase). A termination visit oc-
curred within ~ 14 days after the last dose of lesinurad.
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Efficacy assessments in the core studies were continued
through month 12 of the extension study. The primary
endpoint of the extension study was the proportion of
patients who experienced complete resolution of at least
one target tophus at each monthly visit and overall. Sec-
ondary tophus endpoints were the proportion of patients
with best tophus response (complete or partial reso-
lution) of at least one target tophus at each visit and
overall, and the mean change and mean percentage
change from core study baseline in the sum of areas for
all target tophi at each visit.
The key secondary endpoint was the mean rate of gout
flares requiring treatment in the period from the end of
extension month 2 to the end of extension month 12,
recorded by patients via electronic diary. Secondary
endpoints included the proportion of patients with sUA
< 5.0 mg/dl (primary endpoint in the core study), as well
as < 4.0 and < 3.0 mg/dl, at each monthly visit up to
month 12 in the extension study. Absolute and percent-
age changes in sUA from the core study baseline were
also measured at each visit.
Safety assessments
Safety assessments throughout the extension study in-
cluded the incidence and severity of treatment-
emergent adverse events (TEAEs; coded according to
Medical Dictionary for Regulatory Activities version
14.0) and their relationship to study medication, TEAEs
leading to withdrawal, and serious adverse events
(SAEs). Renal safety assessments consisted of renal-
related and kidney stone TEAEs (itemized in Additional
file 1: Table S1) and instances of sCr elevation greater
than or equal to 1.5 times and greater than or equal
to 2.0 times baseline. Assessments of cardiovascular
TEAEs included cardiovascular-related AEs and rates
of major adverse cardiovascular events (MACE) (i.e.,
cardiovascular death, nonfatal myocardial infarction,
and nonfatal stroke) [14]. Clinical laboratory evalua-
tions (hematology, serum chemistry, and urinalysis) and
vital sign assessments were performed at planned monthly
assessments. Safety data were reviewed by an independent
data monitoring committee, renal events adjudication
committee, and cardiovascular endpoints adjudication
committee appointed by the study sponsor.
Statistical analysis
Efficacy and safety analyses used the intention-to-treat
and safety populations, respectively. The intention-to-
treat population included all randomized patients who re-
ceived at least one dose of lesinurad in the extension study
and had at least one postbaseline efficacy measurement.
The safety population included all patients who received
at least one dose of lesinurad in the extension study.Tophus resolution rates were compared between treat-
ment groups in each time interval and tested using the
Cochran–Mantel–Haenszel test statistic, stratifying by
core study to account for any study-specific sUA-lowering
effect and by core day − 7 renal function (randomized
values). Rates of gout flares requiring treatment were
compared between groups by adding the number of flares
in each time interval. Estimates of the adjusted rate of
gout flares requiring treatment were obtained from nega-
tive binomial regression adjusted by day − 7 renal function
and day − 7 sUA status (randomized values) and log
follow-up time as the offset variable.
Proportions of patients at each scheduled visit who
achieved sUA < 5.0, < 4.0, and < 3.0mg/dl were tabulated
for each treatment group. Analyses used missing value im-
putation (i.e., patients with missing data were considered
nonresponders), observed cases, and last observation car-
ried forward imputation. sUA levels during the extension
study were analyzed using an analysis of covariance model
with baseline value as a covariate and treatment group
and core day − 7 sUA status as factors (randomized
values) for the intention-to-treat population.
TEAEs were defined as AEs that started on or after the
first lesinurad dose in the extension study or AEs that
started before the first lesinurad dose but worsened during
the extension study. TEAEs are presented as cumulative
results throughout the extension study. TEAEs were also
calculated as exposure-adjusted incidence rates (number
of patients with events per 100 person-years [PY]) to ad-
just for differences in duration of lesinurad exposure in
the four treatment groups. Exposure-adjusted incidence
rates are presented for the core study and for the core plus
12months of the extension study.
Descriptive statistics are provided for safety data, with
categorization according to randomized treatment group.
For patients whose lesinurad dose was decreased from
400 to 200mg daily at extension month 12, according to
protocol amendment, safety analyses are allocated to
the initial randomized dose. All analyses were per-
formed with SAS software version 9.1.3 or higher (SAS
Institute, Cary, NC, USA).
Results
Patient disposition
Of the 324 patients who enrolled in the core study, 235
(72.5%) completed the 12months of treatment. A total of
196 patients (83.4%) enrolled in the extension study and
received at least one dose of lesinurad (Additional file 1:
Figure S1). There were 149 (76.0%) patients who com-
pleted the study through extension month 12 and 124
(63.3%) who completed through extension month 24.
Altogether, 88 patients (44.9%) discontinued the study
early, with similar percentages in all treatment groups.
The most common reasons for early study termination
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200CONT, 12.1% in 200CROSS, 26.2% in 400CONT,
and 17.6% in 400CROSS, respectively) and AEs (14.1%
of patients in 200CONT, 6.1% in 200CROSS, 13.8% in
400CONT, and 17.6% in 400CROSS). Demographic and
baseline characteristics at the time of core study initi-
ation were similar across the extension treatment
groups (Table 1).Study medications
The median [range] of lesinurad exposure in days (in-
clusive of dose interruptions) in the extension study
was comparable between the four groups (200CONT,
792 [39, 1154]; 200CROSS, 799 [1, 1178]; 400CONT,
826 [36, 1191]; 400CROSS, 776 [12, 1084]). Lesinurad
exposure in the core plus extension was greater in the
CONT groups (200CONT, 1134 [373, 1495]; 400CONT,
1155 [372, 1523]) than the CROSS groups (200CROSS,
799 [1, 1178]; 400CROSS, 776 [12, 1084]). Expressed as
PY, lesinurad exposure in core plus extension studies
was 173.6, 61.9, 180.6, and 61.7 PY in the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, respect-
ively. Median compliance with lesinurad during the
extension study was > 97% in all groups. The lesinurad
dose was decreased, per the protocol amendment, from
400 to 200 mg/day in 47 patients.Table 1 Demographic and baseline characteristics of extension stud
Parameter 200CONT (n = 64)
Age, years, mean (SD) 53.2 (10.4)
Male sex, n (%) 63 (98.4)
Race, n (%)
Asian 5 (7.8)
Black or African American 9 (14.1)
Māori 0
White 48 (75.0)
Body mass index, kg/m2, mean (SD) 31.9 (5.9)
Duration since gout diagnosis, years, mean (SD) 15.8 (9.5)
Number of gout flares in past 12 months, mean (SD) 7.7 (13.6)
Type of gout flare prophylaxis, n (%)
Colchicine 55 (85.9)
NSAID 6 (9.4)
Both 1 (1.6)
Other/missing 4 (6.3)
sUA, mg/dl, mean (SD)
At core study baselinea 5.4 (1.6)
At extension study start 4.0 (2.2)
Abbreviations: CONT Continuation of lesinurad treatment, CROSS Crossover from cor
drug, sUA Serum urate
aFollowing 3 weeks of febuxostat 80 mg dailyEfficacy assessments
Tophus resolution and area reduction
The proportion of patients with complete resolution of
at least one target tophus increased in all groups with
exposure to combination therapy in the extension study
(Fig. 1a). By month 12 in the extension study, 59.6%,
43.5%, 66.7%, and 50.0% of patients in the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, respect-
ively, had complete resolution of at least one target to-
phus. The proportions of patients who experienced
complete or partial resolution of at least one target to-
phus by month 12 of the extension study were 74.5%,
82.6%, 84.3%, and 80.8%, respectively.
The percentage reductions from the core study base-
line in the sum of the areas for all target tophi were
76.4%, 58.1%, 77.5%, and 62.8% for the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, re-
spectively, at extension month 12 (Fig. 1b). The differ-
ence in the percentage reduction between 200CROSS
and 200CONT (− 21.55 [95% CI, – 45.44, 2.35]) was not
significant (p = 0.076), whereas the difference between
400CROSS and 400CONT (− 15.98 [95% CI, – 42.72,
10.75] was not different (p = 0.24).
Gout flares requiring treatment
The adjusted mean (SE) rates of gout flares requiring
treatment from the end of extension month 2 to they groups at the start of the core study (safety population)
200CROSS (n = 33) 400CONT (n = 65) 400CROSS (n = 34)
52.4 (10.1) 52.1 (11.5) 52.1 (10.6)
33 (100) 60 (92.3) 32 (94.1)
3 (9.1) 5 (7.7) 1 (2.9)
4 (12.1) 8 (12.3) 1 (2.9)
0 2 (3.1) 0
26 (78.8) 49 (75.4) 31 (91.2)
33.9 (6.1) 31.8 (5.8) 33.4 (5.9)
13.8 (9.0) 12.9 (10.0) 12.0 (9.3)
7.1 (5.8) 8.1 (8.2) 7.1 (5.9)
24 (72.7) 53 (81.5) 30 (88.2)
3 (9.1) 12 (18.5) 4 (11.8)
0 2 (3.1) 0
6 (18.2) 2 (3.1) 0
4.9 (1.3) 5.0 (1.5) 5.3 (1.4)
5.2 (1.7) 2.9 (1.7) 5.5 (2.4)
e study placebo to lesinurad treatment, NSAID Nonsteroidal anti-inflammatory
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1.3 (0.48) for 200CROSS, 0.2 (0.08) for 400CONT, and 1.9
(0.93) for 400CROSS. The adjusted rate was 90% lower
with 400CONT than with 400CROSS (incidence rate ratio
[95% CI] CROSS vs. CONT = 0.1 [0.0–0.4]; p = 0.0007)
but was not significantly lower with 200CONT than with
200CROSS (incidence rate ratio = 0.5 [0.2–1.2]; p = 0.13).
The proportion of patients requiring treatment for a
gout flare generally decreased over time in the core and
extension studies for all groups (Fig. 2). Proportions of
patients with a gout flare requiring treatment between
extension months 2 and 12 were lowest in the
400CONT group (9.2%) and highest in the 400CROSS
and 200CONT groups (35.5%), with the 200CROSS
group being intermediate (27.4%).
sUA endpoints
The proportion of patients with sUA < 5.0 mg/dl during
the core study ranged from 68.8% to 79.7% in the
200CONT group and 84.4% to 96.9% in the 400CONT
group (Fig. 3a). These proportions were maintained
during 12 months of the extension study in both the
200CONT (range, 64.5–77.1%) and 400CONT (range,
81.6–93.6%) groups. In the 200CROSS and 400CROSS
groups, the proportion of patients with sUA < 5.0 mg/dl
at each study visit ranged from 53.1% to 65.6% and
from 38.2% to 55.9%, respectively, during the core study
while receiving febuxostat alone. This proportion in-
creased during the extension study in both the 200CROSS
(range, 70.4–88.9%) and 400CROSS (range, 71.4–93.3%)
groups. The same trends were also observed with targets
of < 4.0 and < 3.0mg/dl (data not shown).
At the end of the core studies, mean sUA was signifi-
cantly lower in patients treated with combined lesi-
nurad and febuxostat than in those treated withFig. 2 Percentage of patients with gout flare requiring treatment in intenti
months. CONT Continuation of lesinurad treatment, CROSS Crossover fromfebuxostat alone (p < 0.0001, all group comparisons)
(Fig. 3b). In the extension study, mean sUA levels in
the crossover groups were reduced after 1 month of
lesinurad treatment; in subsequent months, sUA levels
were similar between the 200CONT and 200CROSS
groups and between the 400CONT and 400CROSS
groups. After 12months in the extension study, mean
(SD) sUA levels were 3.9 [1.9], 3.8 [1.6], 3.0 [1.6], and 4.2
[3.0] mg/dl for the 200CONT, 200CROSS, 400CONT, and
400CROSS groups, respectively.
Safety assessments
Adverse events
At least one TEAE was experienced in the extension study
by 78.1%, 81.8%, 87.7%, and 97.1% of the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, respect-
ively. Serious TEAEs were reported in 14.1%, 9.1%, 13.8%,
and 14.7% of the respective groups, and TEAEs led to
study withdrawal in 15.6%, 6.1%, 14.8%, and 14.7%. The
most common individual TEAEs (in > 5% patients in any
group) during the extension study were nasopharyngitis,
hypertension, and increased blood creatinine (Additional
file 1: Table S2). For patients (n = 47) whose lesinurad dose
decreased from 400 to 200mg daily per the protocol
amendment, there were no notable safety findings com-
paring post- versus predose change.
In the core study, the exposure-adjusted incidence
rates of any TEAE were 90.9 for the 200CONT group
and 93.0 for the 400CONT group (Table 2). With
longer exposure to lesinurad in the core plus extension,
the exposure-adjusted incidence rates for the
200CONT and 400CONT groups were 34.0 and 34.3,
respectively. The exposure-adjusted incidence rates of
any serious TEAE were 5.1 and 6.6, respectively, in the
core study and 6.3 and 6.6 in the core plus extension.on-to-treat population receiving lesinurad + febuxostat up to 24
core study placebo to lesinurad treatment
ab
Fig. 3 Proportion of patients with complete resolution of at least one target tophus (a) and percentage mean change from baseline in target
tophus area (b) up to 24months on lesinurad + febuxostat: observed cases. CONT Continuation of lesinurad treatment, CROSS Crossover from core
study placebo to lesinurad treatment
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posed to lesinurad in the core study, so all PYs were cal-
culated as patients with events per 100 PY of placebo
(febuxostat) exposure. With exposure to lesinurad in the
core plus extension, the exposure-adjusted incidence
rates of any TEAE were 45.2 for the 200CROSS group
and 53.5 for the 400CROSS group. Exposure-adjusted
incidence rates of any serious TEAE were 4.8 and 8.1 for
the 200CROSS and 400CROSS groups, respectively.
Renal-related adverse events
The proportions of patients who experienced at least
one renal-related AE in the extension study were
25.0%, 6.1%, 21.5%, and 23.5% for the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, respect-
ively. The most common individual renal-related AEwas increased blood creatinine (15.6%, 3.0%, 13.8%, and
11.8%, respectively). The only renal-related SAEs were
experienced by one patient (1.6%) in the 200CONT
group (renal impairment), one (1.5%) in the 400CONT
group (acute renal failure), and one (2.9%) in the
400CROSS group (acute renal failure). No patients
underwent hemodialysis. The exposure-adjusted inci-
dence rates of any renal-related TEAE were 6.7 for the
200CONT group and 10.0 for the 400CONT group in
the core study and 9.8 and 9.4, respectively, in the core
plus extension (Table 2). The exposure-adjusted incidence
rates were 3.2 and 13.0 for the 200CROSS and 400CROSS
groups, respectively, in the core plus extension.
Altogether, ten kidney stone TEAEs were reported in
ten patients during the extension study, three of which
were SAEs (400CONT, 2; 400CROSS, 1). All ten
Table 2 Summary of exposure-adjusted incidence rates of treatment-emergent adverse events during the core study and the core
study + extension study (safety population)
System organ class
Preferred term [n (exposure-
adjusted rate)]
Core study Core + extension study
200CONT
(n = 64)
(PY = 59.4)
200CROSS
(n = 33)
(PY = 30.6)a
400CONT
(n = 65)
(PY = 60.2)
400CROSS
(n = 34)
(PY = 31.5)a
200CONT
(n = 64)
(PY = 173.6)
200CROSS
(n = 33)
(PY = 61.9)
400CONT
(n = 65)
(PY = 180.6)
400CROSS
(n = 34)
(PY = 61.7)
Any TEAE 54 (90.9) 20 (65.4) 56 (93.0) 29 (92.1) 59 (34.0) 28 (45.2) 62 (34.3) 33 (53.5)
Any serious TEAE 3 (5.1) 1 (3.3) 4 (6.6) 1 (3.2) 11 (6.3) 3 (4.8) 12 (6.6) 5 (8.1)
Any fatal TEAE 0 0 0 0 1 (0.6) 0 0 0
Any renal-related TEAE 4 (6.7) 3 (9.8) 6 (10.0) 0 17 (9.8) 2 (3.2) 17 (9.4) 8 (13.0)
Any serious renal-related TEAE 0 0 0 0 1 (0.6) 0 1 (0.6) 1 (1.6)
Any kidney stone AE 0 0 1 (1.7) 1 (3.2) 3 (1.7) 1 (1.6) 5 (2.8) 2 (3.2)
Any serious kidney stone AE 0 0 0 1 (3.2) 0 0 2 (1.1) 1 (1.6)
sCr elevation 1.5× baseline 3 (5.1) 0 7 (11.6) 2 (6.3) 10 (5.8) 6 (9.7) 18 (10.0) 7 (11.3)
sCr elevation 2.0× baseline 2 (3.4) 0 3 (5.0) 0 6 (3.5) 0 4 (2.2) 4 (6.5)
MACE 0 0 1 (1.7) 0 1 (0.6) 0 2 (1.1) 0
Adjudicated cardiovascular events 3 (5.1) 0 3 (5.0) 0 4 (2.3) 1 (1.6) 4 (2.2) 2 (3.2)
Abbreviations: CONT Continuation of lesinurad treatment, CROSS Crossover from core study placebo to lesinurad treatment, MACE Major adverse cardiovascular
event (nonfatal myocardial infraction, nonfatal stroke, cardiovascular death), PY Person-years of lesinurad exposure, sCr Serum creatinine, TEAE Treatment-
emergent adverse event
aPY are person-years of placebo (febuxostat) exposure
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quired by the protocol. The incidence of kidney stone
AEs was comparable between the 200CONT plus
200CROSS groups (4.1%; four patients) and the
400CONT plus 400CROSS groups (6.1%; six patients);
seven of the ten kidney stone TEAEs occurred in patients
randomized to lesinurad in the core study. The
exposure-adjusted incidence rates for kidney stones in the
core study were 0, 0, 1.7, and 3.2 for the 200CONT,
200CROSS, 400CONT, and 400CROSS groups, respect-
ively, and 1.7, 1.6, 2.8, and 3.2, respectively, in the core
plus extension (Table 2).Cardiovascular-related adverse events
During the extension study, events adjudicated by the
Cardiovascular Endpoints Adjudication Committee as
cardiovascular events occurred in 4.7%, 3.0%, 1.5%,
and 5.9% of patients in the 200CONT, 200CROSS,
400CONT, and 400CROSS groups, respectively. There
was a MACE in each CONT group and none in the
CROSS groups.
The exposure-adjusted incidence rates of patients with
events adjudicated as cardiovascular events in the core
study were 5.1 for the 200CONT group and 5.0 for the
400CONT group and 2.3 and 2.2, respectively, in the
core plus extension (Table 2). The exposure-adjusted in-
cidence rates were 1.6 and 3.2 for the 200CROSS and
400CROSS groups in the core plus extension study. The
exposure-adjusted incidence rates for MACE in the core
were 0, 0, 1.7, and 0 for the 200CONT, 200CROSS,400CONT, and 400CROSS groups, respectively, and 0.6,
0, 1.1, and 0, respectively, in the core plus extension and
core plus extension.
Laboratory evaluations and vital signs
In the extension study, sCr elevation greater than or
equal to 1.5 times baseline (baseline defined as the sCr
value prior to starting lesinurad) occurred in 15 (15.5%)
patients (19 elevations) in the 200CONT and 200CROSS
groups and in 21 (21.2%) patients (23 elevations) in the
400CONT and 400CROSS groups (Table 3). Resolution
of sCr elevations (defined as sCr less than or equal
to 1.2 times baseline) occurred in 57–100% of cases and
without an interruption of lesinurad treatment in 57–
100% of cases (Table 3).
sCr elevation greater than or equal to 2.0 times base-
line occurred in four (4.1%) patients (four elevations)
in the 200CONT plus 200CROSS groups and six
(7.1%) patients (seven elevations) in the 400CONT
plus 400CROSS groups (Table 3). Resolution of sCr el-
evations occurred in 100% of cases, 25–100% without
an interruption of lesinurad treatment (Table 3).
Exposure-adjusted incidence rates of sCr greater than or
equal to 1.5 times baseline were 5.1 and 11.6 for the
200CONT and 400CONT groups, respectively, in the core
study and 5.8 and 10.0, respectively, in the core plus ex-
tension (Table 2). Exposure-adjusted incidence rates for
sCr greater than or equal to 1.5 times baseline in the
200CROSS and 400CROSS groups in the core plus exten-
sion were 9.7 and 11.3, respectively. Exposure-adjusted in-
cidence rates of sCr greater than or equal to 2.0 times
Table 3 Incidence of serum creatinine elevations during the extension study
Serum creatinine criterion 200CONT
(N = 64)
n (%)
200CROSS
(N = 33)
n (%)
400CONT
(N = 65)
n (%)
400CROSS
(N = 34)
n (%)
sCr elevation ≥ 1.5× lesinurad baselinea
Number of patients with elevation 9 (14.1) 6 (18.2) 14 (21.5) 7 (20.6)
Number of elevations 12 7 15 8
Number (%) resolutionsb 10/12 (83.3) 4/7 (57.1) 14/15 (93.3) 8/8 (100)
Number (%) resolutions after interruption of study medication 3/12 (25.0) 0/7 (0) 5/15 (33.3) 0/8 (0)
Number (%) resolutions without interruption of study medication 7/12 (58.3) 4/7 (57.1) 9/15 (60.0) 8/8 (100)
Number (%) unresolved at last visit 2/12 (16.7) 3/7 (42.9) 1/15 (6.7) 0/8 (0)
sCr elevation ≥ 2.0× lesinurad baselinea
Number of patients with elevation 4 (6.3) 0 (0) 2 (3.1) 4 (11.8)
Number of elevations 4 0 2 5
Number (%) resolutionsb 4/4 (100) 0/0 (0) 2/2 (100) 5/5 (100)
Number (%) resolutions after interruption of study medication 3/4 (75.3) 0/0 (0) 1/2 (50.0) 0/5 (0)
Number (%) resolutions without interruption of study medication 1/4 (25.0) 0/0 (0) 1/2 (50.0) 5/5 (100)
Number (%) unresolved at last visit 0/4 (0) 0/0 (0) 0/2 (0) 0/5 (0)
Abbreviations: CONT Continuation of lesinurad treatment, CROSS Crossover from core study placebo to lesinurad treatment, sCr serum creatinine
aLesinurad baseline is before starting lesinurad therapy; for CONT groups, at the start of the core study; for CROSS groups, at the start of the extension study
bResolution defined as sCr value ≤ 1.2× baseline following an elevation
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400CONTgroups, respectively, in the core study and
3.5 and 2.2, respectively, in the core plus extension.
Exposure-adjusted incidence rates for sCr greater than
or equal to 2.0 times baseline in the 200CROSS and
400CROSS groups in the core plus extension were 0
and 6.5, respectively. Other clinical safety laboratory
values and vital signs were generally similar across
treatment groups, with no notable changes from base-
line in any group.
Discussion
The goal of gout management is to achieve a sustained low-
ering in sUA levels, recommended at < 6.0 or < 5.0mg/dl
according to the severity of gout symptoms [1, 2]. Few con-
trolled studies to date have investigated the efficacy of ULTs
to maintain sUA levels at target and the effects of sustained
sUA lowering on gout symptoms.
In the CRYSTAL phase III trial, after 12months, com-
bination therapy with lesinurad and febuxostat 80mg was
shown to maintain sUA < 5.0 mg/dl in ~ 57% and ~ 61% of
patients in the 200-mg or 400-mg lesinurad dose groups,
respectively, compared with ~ 41% of patients treated with
febuxostat 80mg alone [11]. Patients who entered the
extension study represent a subset of the core study popu-
lation: those who were able to tolerate the study medica-
tions and who completed the core study treatment. For
those in the extension study who continued to receive
combination therapy, sUA lowering was sustained without
attenuation over 12months. For those who crossed overfrom receiving febuxostat alone to receiving combination
therapy, the proportions of patients achieving target sUA
increased, reaching proportions similar to the groups that
continued lesinurad therapy at the end of month 12.
By the end of the core study, there was a numerical
increase in the proportion of patients with complete
resolution of at least one target tophus with combin-
ation therapy compared with febuxostat alone, but dif-
ferences were not statistically significant [13]. The
proportion of patients with complete tophus resolution
continued to increase during the extension study,
reaching nearly two-thirds of patients by extension
month 12. There was also a significant, almost 50%
greater, reduction in target tophus area with lesinurad
200 mg plus febuxostat and lesinurad 400 mg plus
febuxostat groups compared with febuxostat alone at
the end of the core study. Tophus area continued to de-
crease during the extension study, declining by as much
as 78% at extension month 12. The improvement in to-
phus regression in all groups during the extension was
not unexpected, because the mean sUA at the start of
the extension was < 6 mg/dl even for the groups receiv-
ing febuxostat alone during the core study, and the
sUA was maintained or reduced further throughout the
extension with the more intensive ULT. However,
longer-term treatment may be needed to further dis-
solve baseline tophi, particularly to demonstrate differ-
ences in treatment [15, 16].
Patients who received lesinurad in the core study
and continued in the extension study had the lowest
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lower in the 400CONT group than the 200CONT
group. The gout flare rates were higher in patients in
the crossover groups where they only had up to 12
months of combination therapy. As expected with the
initiation of an effective ULT, rates of gout flares
requiring treatment initially increased in patients pre-
viously on 12 months of febuxostat monotherapy in
the core study when they began lesinurad combination
therapy in the extension study. The proportion of pa-
tients who had a gout flare requiring treatment gener-
ally declined over time in all the treatment groups,
demonstrating the benefit of continued sUA lowering.
Gout flares and tophi can seriously impair the quality of
life in patients with gout [17–20]. Appropriate ULT that
effectively lowers and maintains sUA at target levels can
reduce the frequency of gout flares [18, 20, 21] and the
size and number of tophi [5, 18, 21], leading to an im-
proved quality of life [22–24]. Although not addressed in
the present study, an improvement in quality of life would
be consistent with the observed reduction in gout flares
and increased tophus resolution as a result of lower sUA
levels with lesinurad plus febuxostat treatment. The
present results are also consistent with the conclusion that
more than 1 year of ULT is required to reduce gout flares
and increase tophus resolution, presumably because it
takes time to reduce the body urate load [16, 25, 26].
Consistent with safety outcomes in the core study, treat-
ment with lesinurad 200mg in combination with febuxo-
stat in the core and extension studies was generally well
tolerated in patients with tophaceous gout. For those pa-
tients who entered the extension study and had tolerated
therapy in the core study, some developed renal-related
AEs, including sCr elevations during the extension study.
Thus, ongoing monitoring of kidney function is important
for patients receiving lesinurad therapy on a long-term
basis. No new safety signals were observed, because the
exposure-adjusted incidence rates of TEAEs in the core
plus extension studies were not greater than those in the
core study alone. The combination of lesinurad 400mg
plus febuxostat was associated with a higher incidence of
sCr elevations than with lesinurad 200mg plus febuxostat.
Resolution of sCr elevations occurred by the last visit in
the majority of patients in all treatment groups.
Limitations of the extension study that are shared with
the core study include the small number of women in the
study and imprecision in the methodology for measuring
flares and tophus resolution. Also, patients who entered
the extension study are a subset of the core study popula-
tion: those who were able to tolerate the study medica-
tions and who completed the core study treatment. As
mentioned above, although there was continued reduction
in tophus area with treatment time in this study,
treatment for longer than 2 years may be needed tofurther resolve baseline tophi, particularly to demonstrate
differences in treatment [15, 16].
Conclusions
In this extension study, continued combination therapy
with lesinurad and febuxostat maintained lower sUA
levels for up to 24months in patients with tophaceous
gout who were unable to achieve target sUA on febuxo-
stat alone. There was a persistent trend toward reso-
lution of tophi and reduction in the rate of flares. No
new safety concerns were evident with longer exposure
to combination therapy. Renal-related AEs, including
sCr elevations, were observed after the first year of treat-
ment, and ongoing monitoring of kidney function is im-
portant for patients receiving lesinurad therapy on a
long-term basis. These data provide further support for
combining a uricosuric with a xanthine oxidase inhibitor
in the treatment of patients with tophaceous gout.
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